Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGDR2 | Q9Y5Y4 | 3/20 | 0.51 |
| ▸ | PTGER4 | P35408 | 6/20 | 0.46 |
| ▸ | KCNK3 | O14649 | 1/20 | 0.46 |
| ▸ | ESR1 | P03372 | 1/20 | 0.44 |
| ▸ | CFTR | P13569 | 1/20 | 0.44 |
| ▸ | F2RL3 | Q96RI0 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4682043 | 0.88 | PTGER4 (0.50) | PTGDR2PTGER4KCNK3 | |
| SCHEMBL4682706 | 0.86 | PTGER4 (0.48) | PTGDR2PTGER4F2RL3 | |
| SCHEMBL4681192 | 0.85 | TRPM2 (0.41) | PTGDR2PTGER4KCNK3ESR1 | |
| SCHEMBL4685142 | 0.81 | SCN9A (0.42) | PTGDR2 | |
| SCHEMBL4688302 | 0.79 | GRN (0.47) | — | |
| SCHEMBL4006704 | 0.75 | POLB (0.58) | PTGDR2 | |
| SCHEMBL28818513 | 0.73 | KCNK3 (0.61) | PTGDR2KCNK3ESR1 | |
| SCHEMBL30928902 | 0.72 | CFTR (0.63) | PTGDR2ESR1CFTR | |
| SCHEMBL25344303 | 0.72 | PTGER4 (0.74) | PTGER4 | |
| Trifluoroacetic Acid SCHEMBL28818550 | 0.72 | HTR7 (0.53) | PTGDR2KCNK3ESR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1513796-B1 | PHENYLOXYALKANOIC ACID DERIVATIVES AS HPPAR ACTIVATORS | SMITHKLINE BEECHAM CORP (US) | 2008-02-13 | — | — | EP | disclosed |
| US-7241793-B2 | Phenyloxyalkanonic acid derivatives as hPPAR activators | SMITHKLINE BEECHAM CORPORATION (US) | 2007-07-10 | — | — | US | disclosed |
| US-20050222424-A1 | Phenyloxyalkanonic acid derivatives as hppar activators | SMITHKLINE BEECHAM CORPORATION | 2005-10-06 | — | — | US | disclosed |
| EP-1513796-A2 | PHENYLOXYALKANOIC ACID DERIVATIVES AS HPPAR ACTIVATORS | SMITHKLINE BEECHAM CORPORATION (US) | 2005-03-16 | — | — | EP | disclosed |
| WO-2004000785-A2 | PHENYLOXYALKANONIC ACID DERIVATIVES AS HPPAR ACTIVATORS | SMITHKLINE BEECHAM CORPORATION (US) | 2003-12-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050222424-A1 | Phenyloxyalkanonic acid derivatives as hppar activators | CEL, HPN, LIPA | PTGDR2 494/4885PTGER4 418/4885KCNK3 3477/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.